Cargando…
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
BACKGROUND: A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events. Traditional rule-based designs require temporarily stopping recruitment whilst waiti...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595589/ https://www.ncbi.nlm.nih.gov/pubmed/31242873 http://dx.doi.org/10.1186/s12885-019-5801-3 |